Moody's assigns Al Sirona Acquisition (Zentiva) a first-time rating of B3; outlook stable
18/05/2018 15:27
For the full text of this story please click the following link: http://www.moodys.com/page/viewresearchdoc.aspx?docid=PR_383834&WT.mc_id=AM~UmV1dGVyc05ld3MyX1NCX0NWX1JhdGluZ19OZXdzX0FsbA==~20180518_PR_383834
Recent news on Zentiva SA
See all newsIndia's Biocon climbs on EU nod to generic diabetes, weight-loss medication
Deals of the day-Mergers and acquisitions
Polish drug maker Polpharma working on bid for Advent's Zentiva - sources
Czech generic drug maker Zentiva denies report it is for sale (updated)
Focus: Big pharma and private equity seek healthy returns in Europe's east